Research projects in his own laboratory are aimed at elucidating the mechanisms by which growth factor signaling and transcriptional programs initiate adrenal-specific growth and differentiation with an emphasis on dysregulated adrenocortical stem cells in development and cancer. He is a co-founder of the company Atterocor that focuses on therapies for adrenal cancer. Collaborative work with colleagues has led to the development of new national and international therapeutic trials with biological-based therapies for adrenal cancer that target the molecular defects in cancer while sparing normal tissue. HORM CANC (2015 ) 6:3 DOI 10.1007 
